贝莱特生物 BLTE

Mr. Ita Lu, aged 49, has served as the independent Director of our Company since April 2022. Mr. Lu has also served as the managing partner of Taiwania Capital since May 2018. From 2017 to 2018, Mr. Lu served as the vice president of business development and investor relations of Etana Biotech. From 2009 to 2017, Mr. Lu served as the head of greater China healthcare of KGI Securities. From 2008 to 2009, Mr. Lu served as the equity research analyst of greater China healthcare of Yuanta Research. From 2006 to 2008, Mr. Lu served as the investment manager of China Investment Development Corp. From 2001 to 2006, Mr. Lu served as the investment manager of China Development Industrial Bank. From 1999 to 2001, Mr. Lu served as the research associate of MedImmune, Inc. Mr. Lu received his bachelor's degree in cell structural biology from University of Illinois at Urbana-Champaign and further received his master's degree in biotechnology from Johns Hopkins University. Mr. Lu is also a certified senior securities specialist in Taiwan. Mr. Lu also passed Hong Kong Securities Institute Licensing Examination for Securities and Futures Intermediaries Paper 1.

Dr. Yu-Hsin Lin, aged 48, is our founder and has served as Director of our Company since we established the Company in March 2018 and the Chairman and the Chief Executive Officer of our Company since November 2021. Dr. Lin has also served as the chairman and the chief executive officer of Belite Bio Holdings Corp. (our wholly owned subsidiary incorporated in Delaware) since June 2016 and December 2017, respectively. From June 2016 to December 2017, Dr. Lin also served as the president of Belite Bio Holdings Corp. (our wholly owned subsidiary). Dr. Lin has served as director of RBP4 Pty Ltd (our wholly owned subsidiary in Australia) since August 2018 and the chief executive officer of RBP4 Pty Ltd from April 2021 to June 2024. Dr. Lin has served as director and chief executive officer of Belite Bio (HK) Limited (our wholly owned subsidiary in Hong Kong) since June 2021 and July 2024, respectively. Dr. Lin has served as the president of Belite Bio Holdings Corp. and Belite Bio, LLC (our wholly owned subsidiaries) since October 2021. Dr. Lin has served as director of Belite Bio (Swiss) AG (our wholly owned subsidiary in Switzerland) since September 2025 and as director of Belite Bio Japan Inc. (our wholly owned subsidiary in Japan) since November 2025. Dr. Lin is primarily responsible for the overall management, strategic planning and corporate development of our Company. Dr. Lin is also the founder and has served as the director and the chairman of Lin BioScience, Inc. (Taiwan OTC: 6696), the parent company of our largest shareholder, Lin Bioscience International Ltd., since 2016, and was the chief executive officer of Lin BioScience, Inc. from June 2016 to April 2022. Dr. Lin specializes in multidisciplinary medicine and surgery, where he holds a Master of Medicine and a PhD in Medicine from the University of Sydney. Dr. Lin also received a Specialist Certificate in Clinical Neuroscience from University of Melbourne and a Cancer Therapeutics & Research Certificate from Harvard Medical School. Dr. Lin further received his MBA from Columbia University, University of Hong Kong and London Business School.

Dr. John M. Longo, aged 57, has served as the independent Director of our Company since April 2022. Dr. Longo has also served as a faculty member at Rutgers Business School on a full-time or part-time basis since June 1993, where he is currently distinguished professor of practice in its finance & economics department. Dr. Longo has also been a visiting professor of finance at Global EMBA -Asia, the joint EMBA program of Columbia Business School, London Business School, and the University of Hong Kong from 2016 to 2022. Dr. Longo served as chief investment officer for two wealth management firms since October 2002, first with the MDE Group and then with Beacon Trust after its acquisition of the MDE Group in 2015. Dr. Longo has also served as the president of Cliff House Capital Management and its predecessor, Cyborg Capital Management, since March 2000. Cliff House Capital Management is primary used as a holding company for Dr. Longo's non-academic activities. Dr. Longo was previously a vice president in the management science group at Merrill Lynch & Co., Inc., having worked as a quantitative investment analyst for the firm from 1997 to 2000. Dr. Longo received his bachelor's degree in economics and computer science from Rutgers College in 1991. Dr. Longo further received his PhD and master of business administration in finance from Rutgers Business School in 1995. Dr. Longo has been a CFA Charter holder since 1998.

Ms. Xiao - Hui Chen, aged 38, has served as a Director of our Company since April 2025. She has served as the senior finance manager of Lin BioScience, Inc. (Taiwan OTC: 6696), the parent company of our largest shareholder, Lin Bioscience International Ltd., since February 2025. From September 2017 to February 2025, she also held other positions at Lin BioScience, Inc., including finance manager and finance assistant manager. From 2014 to 2017, Ms. Chen served as accounting section manager and accounting specialist at ANT Precision Industry Co., Ltd. (Taiwan OTC: 3646). From 2012 to 2014, Ms. Chen served as senior auditor at Deloitte Taiwan. Ms. Chen received her master's degree in accounting and information technology from National Chung Cheng University.

Ms. Wan-Shan Chen, aged 40, has served as a Director of our Company since November 2021. She has served as the chief financial officer of Lin BioScience, Inc. (Taiwan OTC: 6696), the parent company of our largest shareholder, Lin Bioscience International Ltd., since April 2023. She served as the finance director of Lin BioScience, Inc. from July 2022 to April 2023 and also served as associate finance director of Lin BioScience, Inc. from January 2019 to July 2022. From November 2017 to January 2019, Ms. Chen worked as the senior finance manager of Lin BioScience, Inc. From June 2016 to October 2017, Ms. Chen worked as the finance manager of Lin BioScience, Inc. From 2014 to 2016, Ms. Chen was finance manager of Cvie Therapeutics Limited. From 2009 to 2014, Ms. Chen worked as assistant manager of audit department of Deloitte Taiwan. Ms. Chen received her master's degree in accounting from National Taipei University. Ms. Chen is also a certified public accountant in Taiwan.

Dr. Nathan L. Mata, aged 60, has served as the Chief Scientific Officer of our Company since November 2021. Dr. Mata has also served as the chief scientific officer of Belite Bio, LLC (our wholly owned subsidiary incorporated in Delaware) since August 2021. Dr. Mata is primarily responsible for overseeing our Company's scientific and clinical activities, including basic and applied research projects and clinical programs, as well as the development of new processes, technologies or products. From 2019 to 2021, Dr. Mata was the principal consultant of clinical development sector of Halloran Consulting Group. From 2018 to 2019, Dr. Mata was the clinical research & operations consultant of Kubota Vision Inc. (formerly Acucela Inc.). From 2015 to 2018, Dr. Mata worked for Trethera Corporation. He acted as the chief operating officer and director of R&D section from 2015 to 2017, and then worked as clinical research & operations consultant from 2017 to 2018. From 2012 to 2015, Dr. Mata was the principal clinical research scientist of Acucela Inc. From 2010 to 2012, Dr. Mata co-founded and served as the chief scientific officer of Revision Therapeutics. From 2006 to 2008, Dr. Mata served as the vice president of R&D of Sirion Therapeutics. He also served as the chief scientific officer and senior vice president of R&D sector in the same company from 2008 to 2010. From 2004 to 2006, Dr. Mata co-founded and served as a director of SYTERA, INC., which was the research and development unit of Sirion Therapeutics. Dr. Mata received his bachelor's degree in biology, master's degree in biochemistry and PhD in neurobiology from University of Texas at San Antonio.

Mr. Hao-Yuan Chuang, aged 42, has served as the Chief Financial Officer of our Company since April 2020 and Director of our Company since November 2021. Mr. Chuang has also served as the director of Belite Bio (HK) Limited (our wholly owned subsidiary in Hong Kong) since June 2021, as supervisor of Belite Bio (Shanghai) Limited (our wholly owned subsidiary in China) since August 2021, and as the director of RBP4 Pty Ltd (our wholly owned subsidiary in Australia) since May 2022. He is primarily responsible for leading our Company's finance, accounting, investor relations, and capital markets strategy and activities. Mr. Chuang was a director and the chief financial officer of Lin BioScience, Inc. (Taiwan OTC: 6696), the parent company of our largest shareholder, Lin Bioscience International Ltd., from September 2018 to June 2024 and from August 2018 to April 2022, respectively. From December 2017 to August 2018, Mr. Chuang worked as the finance and accounting director of Lin BioScience, Inc. From 2016 to 2017, Mr. Chuang served as the investment director of Suning International Limited. From 2015 to 2016, Mr. Chuang worked as the portfolio manager of The People's Insurance Company (Group) of China Limited (HKG: 1339). From 2013 to 2015, Mr. Chuang was the senior manager of Wanda Hotel Development Company Limited (HKG: 0169). From 2010 to 2013, Mr. Chuang was the manager of corporate finance of CITIC Securities International Company Limited. From 2006 to 2010, Mr. Chuang was the senior associate of Chii Ying Co., Ltd. Mr. Chuang received his bachelor's degree in economics and minor in business administration from National Taiwan University. He received his MBA from Columbia University, University of Hong Kong and London Business School. Mr. Chuang is also a Chartered Financial Analyst and a certified Financial Risk Manager.

Prof. Gary C. Biddle, aged 74, has served as an independent Director of the Company since April 2022. He is professor of financial accounting at University of Melbourne. Prof. Biddle earned his MBA and PhD degrees at University of Chicago. He previously served as professor at University of Chicago, University of Washington, Hong Kong University of Science and Technology (HKUST), and University of Hong Kong (HKU), and as visiting professor at Columbia University and London Business School. In academic leadership, Prof. Biddle served as Dean and Chair Professor at HKU, and as Academic Dean, Council member, and Chair Professor at HKUST. He co-created the EMBA-Global Asia program and taught the first class and decade of the Kellogg-HKUST EMBA program, both ranked #1 by Financial Times or QS. Professionally, he has been a member of AICPA, Australian Institute of Company Directors, CPA Australia, HKICPA, and the editorial boards of premier academic journals. Prof. Biddle also has served as American Accounting Association Executive Board member, Vice-President, and President-Elect nominee, on the Accounting Hall of Fame Selection Committee, Financial Reporting Review Panel of the Financial Reporting Council of Hong Kong, and HKICPA Council. Prof. Biddle's research appears in leading academic journals and in the financial press including CNBC, CNN, SCMP, The Economist, and The Wall Street Journal. He has over 13,000 Google Scholar citations has won 30 teaching honors. He has served as Independent Non-Executive Director of listed and private companies for over 40 cumulative years.

Dr. Hendrik P. N. Scholl, MD, MA, aged 57, has served as the Chief Medical Officer of our Company since September 2024. He is a clinically active retinal expert with more than two decades of expertise in treating retinal diseases, including Stargardt disease and age-related macular degeneration. Dr. Scholl has served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) from 2018 and Chair of the Department of Ophthalmology of the University Hospital Basel from 2016. He has served as President of the European Vision Institute (EVI) since 2018, Chairman of EVICR.net and its Expert Committee on Retinal Dystrophies from 2017, and Founder and President of ARVO-SWISS from 2020. In academia, Dr. Scholl has held leadership roles at key institutions, notably as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School, where he also led the Retinal Degeneration Clinic and the Visual Neurophysiology Service. Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study). He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria. Dr. Scholl graduated from the Eberhard-Karls-University Tubingen, Germany, with a Doctor of Medicine and Master of Arts. He was awarded a research fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology, University College London (UCL), United Kingdom, and later a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the Rheinische Friedrich-Wilhelms-University Bonn, Germany.